Amoytop Biotech concludes IPO fundraising projects, projects operational

Xiamen Amoytop Biotech Co., Ltd. announced the completion of its IPO fundraising projects, including the "Protein Drug Production Expansion and R&D Center Construction Project," "Chronic Hepatitis B Clinical Cure Research Project," and "New Drug R&D Project." The company's board decided to close these projects and cancel related special fundraising accounts.

The IPO, approved by the China Securities Regulatory Commission, involved the public issuance of 46.5 million A shares at an issue price of RMB 8.24 per share, raising a total of RMB 383.16 million. After deducting issuing expenses of RMB 52.7137 million, the net proceeds amounted to RMB 330.4463 million. The projects have reached their intended operational status, with the total planned investment for all three projects standing at RMB 704.5721 million.

As of the announcement date, all IPO funds have been fully invested as planned. The company's "Chronic Hepatitis B Clinical Cure Research Project" secured marketing approval for an expanded indication of Pegabin from the National Medical Products Administration in October 2025. The other two projects, "Protein Drug Production Expansion and R&D Center Construction Project" and "New Drug R&D Project," have fully utilized their allocated IPO funds, with further investments to be made from the company's own capital based on project progress.